Prelude Therapeutics Inc PRLD
We take great care to ensure that the data presented and summarized in this overview for Prelude Therapeutics Inc is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding PRLD
View all-
Orbimed Advisors LLC San Diego, CA10.9MShares$9.38 Million0.38% of portfolio
-
Baker Bros. Advisors LP New York, NY10.1MShares$8.71 Million0.14% of portfolio
-
Black Rock Inc. New York, NY1.07MShares$919,2670.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD1.03MShares$885,1110.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.01MShares$868,9370.0% of portfolio
-
Jacobs Levy Equity Management, Inc Florham Park, NJ667KShares$573,2530.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny635KShares$545,6700.0% of portfolio
-
Massachusetts Financial Services CO Boston, MA494KShares$425,2670.0% of portfolio
-
Acadian Asset Management LLC Boston, MA485KShares$417,4270.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny463KShares$397,7970.0% of portfolio
Latest Institutional Activity in PRLD
Top Purchases
Top Sells
About PRLD
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; PRT3645, a brain penetrant molecule that potently and selectively targets CDK4/6; and PRT-K4 that is in preclinical stage for solid tumors. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.
Insider Transactions at PRLD
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|
Apr 04
2025
|
Jane Huang President, CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,355
-4.29%
|
$0
$0.68 P/Share
|
|
Apr 04
2025
|
Jane Huang President, CMO |
BUY
Exercise of conversion of derivative security
|
Direct |
9,375
+10.7%
|
-
|
|
Mar 25
2025
|
Andrew Combs Chief Chemistry Officer |
BUY
Open market or private purchase
|
Direct |
100,000
+17.24%
|
$0
$0.69 P/Share
|
|
Mar 25
2025
|
Krishna Vaddi CEO |
BUY
Open market or private purchase
|
Direct |
675,000
+25.24%
|
$0
$0.69 P/Share
|
|
Mar 21
2025
|
Krishna Vaddi CEO |
BUY
Open market or private purchase
|
Direct |
15,000
+1.12%
|
$0
$0.73 P/Share
|
|
Mar 20
2025
|
Krishna Vaddi CEO |
BUY
Open market or private purchase
|
Direct |
5,416
+0.41%
|
$0
$0.73 P/Share
|
|
Mar 17
2025
|
Krishna Vaddi CEO |
BUY
Open market or private purchase
|
Direct |
9,106
+0.69%
|
$0
$0.75 P/Share
|
|
Mar 14
2025
|
Krishna Vaddi CEO |
BUY
Open market or private purchase
|
Direct |
29,999
+2.26%
|
$0
$0.75 P/Share
|
|
Mar 13
2025
|
Krishna Vaddi CEO |
BUY
Open market or private purchase
|
Direct |
50,000
+3.8%
|
$0
$0.72 P/Share
|
|
Mar 12
2025
|
Krishna Vaddi CEO |
BUY
Open market or private purchase
|
Direct |
47,500
+3.76%
|
$0
$0.71 P/Share
|
|
Jan 04
2025
|
Jane Huang President, CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,859
-5.31%
|
$3,859
$1.39 P/Share
|
|
Jan 04
2025
|
Jane Huang President, CMO |
BUY
Exercise of conversion of derivative security
|
Direct |
9,375
+11.42%
|
-
|
|
Dec 31
2024
|
Krishna Vaddi CEO |
BUY
Open market or private purchase
|
Indirect |
5,000
+3.39%
|
$5,000
$1.21 P/Share
|
|
Dec 30
2024
|
Krishna Vaddi CEO |
BUY
Open market or private purchase
|
Indirect |
10,000
+6.78%
|
$10,000
$1.2 P/Share
|
|
Dec 23
2024
|
Andrew Combs Chief Chemistry Officer |
BUY
Open market or private purchase
|
Direct |
60,000
+13.71%
|
$60,000
$1.37 P/Share
|
|
Dec 20
2024
|
Andrew Combs Chief Chemistry Officer |
BUY
Open market or private purchase
|
Direct |
3,075
+0.96%
|
$3,075
$1.15 P/Share
|
|
Dec 19
2024
|
Bryant David Lim CLO, CFO, Corp Sec. |
BUY
Open market or private purchase
|
Direct |
25,000
+47.71%
|
$0
$0.91 P/Share
|
|
Dec 19
2024
|
Krishna Vaddi CEO |
BUY
Open market or private purchase
|
Indirect |
6,888
+5.12%
|
$0
$0.89 P/Share
|
|
Dec 18
2024
|
Krishna Vaddi CEO |
BUY
Open market or private purchase
|
Direct |
100,000
+7.89%
|
$0
$0.93 P/Share
|
|
Oct 04
2024
|
Jane Huang President, CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,349
-5.02%
|
$6,698
$2.0 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 1.14M shares |
|---|---|
| Exercise of conversion of derivative security | 37.5K shares |
| Payment of exercise price or tax liability | 13.9K shares |
|---|